Namita Thapar's Emcure Pharma lists at 31% premium on NSE

Emcure Pharmaceuticals, based in India, specialises in the development, manufacturing, and global marketing of pharmaceutical products across various therapeutic areas.

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Emcure Pharmaceuticals shares made a strong debut on July 10 after listing at Rs 1,325.05, a premium of 31.5 percent over the issue price of Rs 1,008.

This follows a successful Initial Public Offering (IPO) that garnered significant investor interest. Emcure's IPO, which ran from July 3 to July 5, is a book-built issue valued at Rs 1,952.03 crores.

QIBs led the bidding, subscribing a massive 92.94 times their allotted quota, while non-institutional investors picked up 42.57 times the reserved portion. Employees of Emcure Pharmaceuticals showed significant interest, placing bids 7.9 times their allotted quota while retail investors bought 6.33 times.

Also Read | Emcure Pharma IPO day 3: Issue subscribed 38x so far, QIBs roar

The IPO includes a fresh issue of 0.79 crore shares, aggregating to Rs 800 crores, and an offer for sale of 1.14 crore shares, totalling Rs 1,152.03 crores. The price band for the IPO was set between Rs 960 and Rs 1,008 per share.

The allotment of shares was finalized on July 8 and Emcure Pharma shares were set to be listed on the BSE and NSE on July 10.

The IPO is managed by Kotak Mahindra Capital Company Limited, Axis Capital Limited, J.P. Morgan India Private Limited, and Jefferies India Private Limited, with Link Intime India Private Ltd acting as the registrar.

Follow our live blog for all the market action

Emcure Pharmaceuticals, based in India, specialises in the development, manufacturing, and global marketing of pharmaceutical products across various therapeutic areas. With a product portfolio that includes orals, injectables, and biotherapeutics, Emcure's reach extends to over 70 countries worldwide.

The company operates 13 manufacturing facilities across India, producing a range of dosage forms including oral solids, oral liquids, and injectables, both liposomal and lyophilized. These facilities are also equipped to manufacture biotherapeutics and complex active pharmaceutical ingredients (APIs) such as chiral molecules, iron molecules, and cytotoxic products.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.